CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 36 enrolled
Drug / intervention
Gefapixant 100 mg +1 moredrug
Likely dose
Gefapixant 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02476890
NCT02476890Phase 2Completed
CompareCT.gov

A Study to Assess the Effect of MK-7264 (AF-219) on Cough Reflex Sensitivity in Both Healthy and Chronic Cough Subjects

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Jun 22, 2015·Updated Jun 18, 2019

In Brief

A Phase 2 clinical trial evaluating Gefapixant 100 mg and Placebo for Refractory Chronic Cough. Completed, enrolled 36 participants.

Detailed Summary

The primary objective of this study was to assess the effect of a single dose of gefapixant 100 mg on cough reflex sensitivity to various challenge agents (capsaicin, citric acid, adenosine triphosphate \[ATP\], and distilled water) in healthy and chronic cough participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Chronic Cough
Countries--
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 22, 2015
Enrollment StartOct 28, 2015
Primary CompletionOct 20, 2016
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 11.0 years ago

Interventions

Gefapixant 100 mgdrug

Gefapixant 100 mg (2 x 50 mg tablets), administered orally as a single dose in treatment Period 1 or treatment Period 2

Placebodrug

Placebo (two tablets matching gefapixant 50 mg), administered orally as a single dose in treatment Period 1 or treatment Period 2